Abstract | BACKGROUND: OBJECTIVE: PATIENTS AND METHODS: This was a prospective, multicenter, phase II trial conducted from October 2013 to August 2017. Major eligibility criteria included KRAS exon 2 wild-type and achievement of complete response, partial response, or continued stable disease for at least 6 months in first-line panitumumab-based therapy. Irinotecan plus panitumumab treatment was continued until disease progression or unacceptable toxicity was observed. The primary endpoint was the 3-month progression-free survival (PFS) rate. RESULTS: Twenty-five patients were enrolled in this study. Their median age was 66.5 years, and the 3-month PFS rate was 50.0% (95% confidence interval 30.0-70.0). The median PFS and overall survival were 3.1 months and 8.9 months, respectively. The response rate and disease control rate were 8.3% and 50.0%, respectively. Common grade 3/4 adverse events were acneiform rash (17%), hypomagnesemia (13%), and dry skin (13%). No treatment-related deaths occurred. CONCLUSION: CLINICAL TRIAL IDENTIFICATION: UMIN000015916.
|
Authors | Akihito Tsuji, Masato Nakamura, Takanori Watanabe, Dai Manaka, Hiroshi Matsuoka, Masato Kataoka, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii |
Journal | Targeted oncology
(Target Oncol)
Vol. 16
Issue 6
Pg. 753-760
(11 2021)
ISSN: 1776-260X [Electronic] France |
PMID | 34718946
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | © 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG. |
Chemical References |
- KRAS protein, human
- Panitumumab
- Irinotecan
- Proto-Oncogene Proteins p21(ras)
- Cetuximab
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Cetuximab
(therapeutic use)
- Clinical Trials, Phase II as Topic
- Colonic Neoplasms
(drug therapy)
- Colorectal Neoplasms
(pathology)
- Humans
- Irinotecan
(pharmacology, therapeutic use)
- Multicenter Studies as Topic
- Panitumumab
(pharmacology, therapeutic use)
- Prospective Studies
- Proto-Oncogene Proteins p21(ras)
(genetics)
|